CJC-1295 + Ipamorelin · Mechanism of Action
Mechanism of Action
In published research, CJC-1295 + Ipamorelin (CJC-1295 No DAC + Ipamorelin) is characterized as a paired research peptides that is studied primarily through its interaction with GHRH receptor (CJC-1295). The summary below describes the mechanisms reported in the scientific literature at a molecular level. It is educational reference information about laboratory study models, not a description of effects in humans.
Reported molecular targets
The research literature associates CJC-1295 + Ipamorelin with GHRH receptor (CJC-1295) and ghrelin / GHS-R1a receptor (Ipamorelin). These are the interaction points most frequently referenced when the compound is discussed in mechanistic studies.
As with any research material, the precise pathways reported vary by model system, and findings are drawn from in-vitro and preclinical work rather than human data.
- Primary target
- GHRH receptor (CJC-1295)
- Also referenced
- ghrelin / GHS-R1a receptor (Ipamorelin)
Where this mechanism is studied
Mechanistic work involving CJC-1295 + Ipamorelin appears most often in the context of growth-hormone-axis research, GH / IGF-1 secretion studies, and dual-stimulation protocol research. Investigators use these model systems to characterize the compound's behavior, not to establish any human application.
Blueprint Labs supplies CJC-1295 + Ipamorelin as a two separate lyophilized vials (≥98% (HPLC + LC-MS verified)) for exactly this kind of controlled laboratory study.
Reading this responsibly
Mechanistic descriptions summarize what researchers have reported about molecular interactions. They are not evidence of safety or benefit in any organism, and they are not instructions for use. For research use only. Not for human consumption, diagnostic, or therapeutic use.
Available from Blueprint Labs
CJC 1295 No DAC + IPA 10mg
Third-party tested, CJC-1295 + Ipamorelin supplied as a research material with a certificate of analysis available.
Questions, answered
What is the reported mechanism of CJC-1295 + Ipamorelin?
Published research describes CJC-1295 + Ipamorelin in terms of GHRH receptor (CJC-1295) and related signaling. This is a generic summary of laboratory findings, not a statement about effects in people.
Does this describe what CJC-1295 + Ipamorelin does in humans?
No. Everything here summarizes in-vitro and preclinical research models. For research use only. Not for human consumption, diagnostic, or therapeutic use.
Is CJC-1295 + Ipamorelin a small molecule or a peptide?
CJC-1295 + Ipamorelin is classified as a paired research peptides (molecular weight 3367.97 g/mol (CJC-1295 No DAC) · 711.85 g/mol (Ipamorelin)).